Sitagliptin and Metformin Hydrochloride Extended-Release Tablets – For Laboratory Use Only

Sitagliptin and Metformin Hydrochloride Extended-Release Tablets – For Laboratory Use Only

(1 条用户评价)

$1.00

Formulated for laboratory research use, Sitagliptin and Metformin Hydrochloride Extended-Release Tablets combine a DPP-4 inhibitor and biguanide. Manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd., approved under H20253718.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare
分类:

描述

Sitagliptin and Metformin Hydrochloride Extended-Release Tablets are a fixed-dose combination widely used in experimental studies involving type 2 diabetes mellitus (T2DM). This dual-action formulation features a DPP-4 inhibitor (sitagliptin) and a biguanide (metformin)—making it highly relevant for glucose metabolism, insulin resistance, and incretin pathway research.

Developed by Qilu Pharmaceutical (Hainan) Co., Ltd., this compound is approved under H20253718 and is intended exclusively for in vitro or in vivo laboratory research.

?? Not for human or animal consumption. For experimental use only.


Product Parameters

Attribute Details
Product Name Sitagliptin and Metformin Hydrochloride ER Tablets
Chinese Name ???????????
CAS (Sitagliptin) 486460-32-6
CAS (Metformin) 657-24-9
Molecular Formula C16H15F6N5O·C4H11N5·HCl
Strength [Specification to be confirmed – typically 50mg/500mg or 100mg/1000mg]
Dosage Form Extended-Release Tablets
Approval Number H20253718 (NMPA China)
Product Code 86905847001237
Manufacturer Qilu Pharmaceutical (Hainan) Co., Ltd.
Storage Store below 25°C; avoid humidity
Packaging Boxed tablets (exact unit count TBD)
Use Restriction Laboratory use only

Mechanism & Research Applications

This combination tablet works via two complementary mechanisms:

  • Sitagliptin inhibits DPP-4, increasing incretin hormones (GLP-1, GIP), enhancing insulin release and reducing glucagon in hyperglycemia.

  • Metformin reduces hepatic glucose production and improves peripheral glucose uptake.

Research applications include:

  • Glucose metabolism and insulin resistance studies

  • Evaluation of incretin pathway regulation

  • Investigations in combination therapy vs monotherapy efficacy

  • Experimental models of T2DM progression and treatment resistance

  • Preclinical pharmacokinetic and bioavailability analysis


Observed Effects in Research

Studies using this combination have reported:

  • Enhanced insulin sensitivity

  • Reduced postprandial glucose spikes

  • Improved ?-cell preservation

  • Attenuated hepatic gluconeogenesis

  • Synergistic glycemic control vs monotherapies


Safety & Handling

  • Use: For in vitro and in vivo research only

  • Protective Measures: Wear gloves, lab coat, and eye protection

  • Storage: Keep sealed, dry, and below 25°C

  • Disposal: As per lab chemical protocols


Research Use Disclaimer

This product is intended strictly for laboratory research use only. It is not for human use, diagnosis, or treatment. Proper lab safety and handling procedures must be followed. Misuse is prohibited and may be subject to local regulations.

其他信息

重量 1 公斤
尺寸 26 × 23 × 26 厘米

Sitagliptin and Metformin Hydrochloride Extended-Release Tablets – For Laboratory Use Only 有 1 个评价

  1. premi

    Thanks

添加评价

您的邮箱地址不会被公开。 必填项已用 * 标注

Q1: Is this tablet suitable for human therapeutic use?

No. This product is labeled for laboratory research only, and not approved for clinical use in humans or animals.

Q2: What are common lab uses of this tablet?

It is widely used to study insulin resistance, incretin hormone regulation, and combined therapy modeling for type 2 diabetes.

Q3: Are COA and SDS available?

Yes. Upon order confirmation, COA (Certificate of Analysis) and SDS (Safety Data Sheet) can be provided upon request.

Q4: Do you accept wholesale orders?

Absolutely. We support both bulk purchases for institutions and small-scale retail orders for individual labs.

Q5: Why is this product valuable in diabetes research?

Because the combination of sitagliptin and metformin targets both incretin degradation and hepatic glucose output, it's ideal for multi-mechanism T2DM research in experimental models.

Q6:What is sitagliptin and metformin hydrochloride as extended-release tablets?

Metformin and sitagliptin combination is used to treat high blood sugar levels caused by type 2 diabetes. Metformin reduces the absorption of sugar from the stomach, reduces the release of stored sugar from the liver.For Research Use Only 


EMI Options

Select at least 2 products
to compare